NASDAQ:ANGN Angion Biomedica (ANGN) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range$1.00▼$10.0052-Week Range N/AVolume224,800 shsAverage Volume86,718 shsMarket Capitalization$30.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Angion Biomedica MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.32% of Float Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment-0.12Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.51) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector649th out of 981 stocksPharmaceutical Preparations Industry313th out of 464 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Angion Biomedica. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.32% of the float of Angion Biomedica has been sold short.Short Interest Ratio / Days to CoverAngion Biomedica has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Angion Biomedica has recently decreased by 1.39%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAngion Biomedica does not currently pay a dividend.Dividend GrowthAngion Biomedica does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngion Biomedica has received a 75.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Angion Biomedica is -0.73. Previous Next 1.0 News and Social Media Coverage News SentimentAngion Biomedica has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Angion Biomedica this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Angion Biomedica insiders have not sold or bought any company stock.Percentage Held by Insiders19.70% of the stock of Angion Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.00% of the stock of Angion Biomedica is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Angion Biomedica are expected to grow in the coming year, from ($1.51) to ($0.53) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Angion Biomedica (NASDAQ:ANGN) StockAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.Read More Receive ANGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGN Stock News HeadlinesJune 1, 2023 | finance.yahoo.comAngion Biomedia Corp. Announces 1-for-10 Reverse Stock SplitMay 2, 2023 | marketwatch.com8-K: Angion Biomedica Corp.June 7, 2023 | Behind the Markets (Ad)WARNING: Do You Invest with these BanksTake a close look at the investment banks above. Because if you have stocks with any of these brokerages... These new political developments WILL affect you.April 27, 2023 | finance.yahoo.comCompanies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite RiskyApril 11, 2023 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVAApril 6, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, ANGN, TIGMarch 27, 2023 | americanbankingnews.comAngion Biomedica (ANGN) Set to Announce Earnings on TuesdayMarch 4, 2023 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLI, DCT, ANGNJune 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!February 24, 2023 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, OSH, IAAJanuary 22, 2023 | benzinga.comMoore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law FirmJanuary 18, 2023 | benzinga.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Angion Biomedica Corp. - ANGNJanuary 17, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Angion Biomedica Corp. MergerJanuary 17, 2023 | marketwatch.comAngion Biomedica Shares Tumble Premarket on Elicio Tie-Up >ANGNJanuary 17, 2023 | technews.tmcnet.comANGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Angion Biomedica Corp. Is Fair to ShareholdersDecember 27, 2022 | finance.yahoo.comBullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)December 22, 2022 | finanznachrichten.deAngion Biomedica Corp.: Angion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsDecember 22, 2022 | finance.yahoo.comAngion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNovember 29, 2022 | nasdaq.comNabriva (NBRV) Posts Positive Data From Cystic Fibrosis StudyNovember 29, 2022 | nasdaq.comAxsome (AXSM) Gains as Alzheimer's Agitation Study Meets GoalNovember 24, 2022 | msn.comReasons to Add Immunovant (IMVT) Stock to Your Portfolio NowNovember 17, 2022 | nasdaq.comImmunovant (IMVT) Rises More Than 150% in 3 Months: Here's HowNovember 10, 2022 | finance.yahoo.comJazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive SalesNovember 4, 2022 | finance.yahoo.comKaruna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 LossNovember 1, 2022 | finance.yahoo.comLilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 ViewOctober 13, 2022 | finance.yahoo.comIs Angion Biomedica (NASDAQ:ANGN) In A Good Position To Deliver On Growth Plans?September 24, 2022 | finance.yahoo.comAngion Biomedica Corp. (ANGN)See More Headlines ANGN Company Calendar Last Earnings11/12/2021Today6/06/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANGN CUSIPN/A CIK1601485 Webwww.angion.com Phone415-655-4899FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,810,000.00 Net MarginsN/A Pretax Margin-4,456.97% Return on Equity-47.53% Return on Assets-40.55% Debt Debt-to-Equity RatioN/A Current Ratio20.00 Quick Ratio20.00 Sales & Book Value Annual Sales$2.30 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / BookN/AMiscellaneous Outstanding Shares30,110,000Free Float24,182,000Market Cap$30.11 million OptionableNot Optionable Beta0.60 Key ExecutivesDr. Jay R. Venkatesan M.B.A. (Age 50)M.D., Ph.D., Pres, CEO & Chairman Comp: $587.1kMr. Gregory S. Curhan (Age 60)Chief Financial Officer Ms. Jennifer J. Rhodes J.D. (Age 52)Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec. Mr. Daniel IazzettiVP of HRBruce RichAssistant Sec.Key CompetitorsVistaGen TherapeuticsNASDAQ:VTGNSio Gene TherapiesNASDAQ:SIOXCytoMed TherapeuticsNASDAQ:GDTCImmix BiopharmaNASDAQ:IMMXKinetaNASDAQ:KAView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 28,685 shares on 5/12/2023Ownership: 0.309%CM Management LLCBought 67,822 shares on 5/8/2023Ownership: 2.657%View All Institutional Transactions ANGN Stock - Frequently Asked Questions Should I buy or sell Angion Biomedica stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Angion Biomedica in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ANGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANGN, but not buy additional shares or sell existing shares. View ANGN analyst ratings or view top-rated stocks. When is Angion Biomedica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our ANGN earnings forecast. How were Angion Biomedica's earnings last quarter? Angion Biomedica Corp. (NASDAQ:ANGN) announced its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The business had revenue of $1.46 million for the quarter, compared to analyst estimates of $1.08 million. When did Angion Biomedica's stock split? Shares of Angion Biomedica reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Angion Biomedica IPO? (ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers. What is Angion Biomedica's stock symbol? Angion Biomedica trades on the NASDAQ under the ticker symbol "ANGN." Who are Angion Biomedica's major shareholders? Angion Biomedica's stock is owned by many different retail and institutional investors. Top institutional investors include CM Management LLC (2.66%) and Renaissance Technologies LLC (0.31%). Insiders that own company stock include Allen Nissenson, Itzhak Goldberg, Jay Venkatesan, Jennifer J Rhodes, Jennifer J Rhodes, John F Neylan and Victor F Ganzi. View institutional ownership trends. How do I buy shares of Angion Biomedica? Shares of ANGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Angion Biomedica make? Angion Biomedica (NASDAQ:ANGN) has a market capitalization of $0.00 and generates $2.30 million in revenue each year. How can I contact Angion Biomedica? Angion Biomedica's mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The official website for the company is www.angion.com. The company can be reached via phone at 415-655-4899 or via email at daniel@lifesciadvisors.com. This page (NASDAQ:ANGN) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Angion Biomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.